139 related articles for article (PubMed ID: 27181727)
1. [Development and perspective for the Biosimilar medicines].
Takayasu Y; Tsukamoto T
Nihon Yakurigaku Zasshi; 2016 May; 147(5):303-9. PubMed ID: 27181727
[No Abstract] [Full Text] [Related]
2. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
3. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
4. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
5. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
6. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
7. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
8. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
9. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
10. [The story of biosimilars--chance or threat?].
Woroń J; Kocić I
Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
12. The use of pharmacometrics to optimize biosimilar development.
Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
[TBL] [Abstract][Full Text] [Related]
13. Drug Development. Are trade secrets delaying biosimilars?
Price WN; Rai AK
Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
[No Abstract] [Full Text] [Related]
14. [First biosimilar infliximab approved].
Neumaier J
MMW Fortschr Med; 2015 Mar; 157 Suppl 1():88. PubMed ID: 26013000
[No Abstract] [Full Text] [Related]
15. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
Pani L; Montilla S; Pimpinella G; Bertini Malgarini R
Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
[TBL] [Abstract][Full Text] [Related]
16. [Cheaper with biosimilars, but safety comes first].
Mellstedt H
Lakartidningen; 2014 May 27-Jun 10; 111(22-23):1011. PubMed ID: 24946487
[No Abstract] [Full Text] [Related]
17. Toward interchangeable biologics.
McCamish M; Pakulski J; Sattler C; Woollett G
Clin Pharmacol Ther; 2015 Mar; 97(3):215-7. PubMed ID: 25670498
[TBL] [Abstract][Full Text] [Related]
18. [Current situations and the future prospect of monoclonal antibody products].
Yamaguchi T
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):36-46. PubMed ID: 25707201
[TBL] [Abstract][Full Text] [Related]
19. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody: the corner stone of modern biotherapeutics.
Xia ZN; Cai XT; Cao P
Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
